Skip header and navigation

1 records – page 1 of 1.

Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke

https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
2217
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Neoplasms
Stroke
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Cancer
Cerebrovascular disease
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
Responsibility
Prepared by: Renal Program
Pamphlet Number
2217
Less detail